AAPL 213.49 1.8171% MSFT 388.56 2.5847% NVDA 121.67 5.2691% GOOGL 165.49 1.6773% GOOG 167.62 1.7544% AMZN 197.95 2.094% META 607.6 2.963% AVGO 195.54 2.1844% LLY 813.48 1.4757% TSLA 249.98 3.8641% TSM 174.09 1.457% V 331.8 0.9892% JPM 232.44 3.2195% UNH 488.65 1.4807% NVO 77.15 1.6603% WMT 85.35 1.0059% LVMUY 132.18 1.865% XOM 111.9 2.9723% LVMHF 662.0 1.0687% MA 527.64 1.5024%
AAPL 213.49 1.8171% MSFT 388.56 2.5847% NVDA 121.67 5.2691% GOOGL 165.49 1.6773% GOOG 167.62 1.7544% AMZN 197.95 2.094% META 607.6 2.963% AVGO 195.54 2.1844% LLY 813.48 1.4757% TSLA 249.98 3.8641% TSM 174.09 1.457% V 331.8 0.9892% JPM 232.44 3.2195% UNH 488.65 1.4807% NVO 77.15 1.6603% WMT 85.35 1.0059% LVMUY 132.18 1.865% XOM 111.9 2.9723% LVMHF 662.0 1.0687% MA 527.64 1.5024%

LeMaitre Vascular Inc

Healthcare US LMAT

81.91USD
3.09(3.92%)

Last update at 2025-03-14T20:00:00Z

Day Range

79.1582.29
LowHigh

52 Week Range

43.9581.68
LowHigh

Fundamentals

  • Previous Close 78.82
  • Market Cap1799.50M
  • Volume157761
  • P/E Ratio52.74
  • Dividend Yield0.80%
  • EBITDA50.44M
  • Revenue TTM199.89M
  • Revenue Per Share TTM8.97
  • Gross Profit TTM 104.90M
  • Diluted EPS TTM1.52

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-310M20M40M60M80M100M120M140M160M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M50M100M150M200M250M300M
Total Assets
Total Liabilities

Change in Cash

2019-12-312020-12-312021-12-312022-12-312023-12-31-14M-12M-10M-8M-6M-4M-2M0M2M4M6M8M10M12M14M

Total Operating Cash

2019-12-312020-12-312021-12-312022-12-312023-12-3114M16M18M20M22M24M26M28M30M32M34M36M38M

Dividends Paid

2019-12-312020-12-312021-12-312022-12-312023-12-310M1M2M3M4M5M6M7M8M9M10M11M12M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 27.49M 34.29M 27.36M 21.68M 28.44M
Minority interest - - - - -
Net income 20.64M 26.91M 21.22M 17.93M 22.94M
Selling general administrative 28.75M 25.50M 22.50M 19.05M 17.69M
Selling and marketing expenses 32.92M 27.66M 23.70M 30.34M 27.32M
Gross profit 104.90M 101.38M 84.62M 79.85M 73.94M
Reconciled depreciation 9.43M 11.07M 8.39M 5.42M 4.32M
Ebit 21.16M 25.55M 19.80M 15.77M 8.94M
Ebitda 30.60M 36.62M 28.20M 21.18M 13.26M
Depreciation and amortization 9.43M 11.07M 8.39M 5.42M 4.32M
Non operating income net other 0.66M 0.08M -0.12200M 0.50M 0.24M
Operating income 21.16M 25.55M 19.80M 15.77M 28.21M
Other operating expenses 131.72M 118.00M 101.05M 96.05M 84.83M
Interest expense 0.99M 2.22M 1.31M 5.91M 0.00200M
Tax provision 6.85M 7.38M 6.14M 3.75M 5.50M
Interest income 0.99M 0.20M 0.21M 0.70M 0.63M
Net interest income 0.99M -2.02200M -1.31000M 0.70M 0.63M
Extraordinary items - - - - 0.40M
Non recurring 3.11M - -0.47000M - -
Other items - - - - -
Income tax expense 6.85M 7.38M 6.14M 3.75M 5.50M
Total revenue 161.65M 154.42M 129.37M 117.23M 105.57M
Total operating expenses 74.96M 64.96M 56.30M 58.67M 53.20M
Cost of revenue 56.76M 53.04M 44.75M 37.38M 31.63M
Total other income expense net 6.33M 8.73M 7.55M 5.91M 7.71M
Discontinued operations - - - - -
Net income from continuing ops 20.64M 26.91M 21.22M 17.93M 22.94M
Net income applicable to common shares 20.64M 26.91M 21.22M 17.93M 22.94M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 346.78M 310.48M 292.80M 252.81M 188.34M
Intangible assets 41.71M 46.53M 52.71M 58.91M 23.19M
Earning assets - - - - -
Other current assets 6.38M 6.73M 4.19M 2.62M 3.31M
Total liab 48.88M 42.27M 38.65M 80.24M 40.20M
Total stockholder equity 297.90M 268.20M 254.15M 172.57M 148.14M
Deferred long term liab - - 0.07M 0.70M 1.18M
Other current liab 23.28M 20.54M 1.27M 0.77M 2.48M
Common stock 0.24M 0.24M 0.23M 0.22M 0.22M
Capital stock 0.24M 0.24M 0.23M 0.22M 0.22M
Retained earnings 115.43M 97.77M 88.12M 70.55M 57.03M
Other liab - 2.24M 2.77M 4.77M 5.39M
Good will 65.94M 65.94M 65.94M 65.94M 41.66M
Other assets - 2.74M 2.13M 18.45M 1.34M
Cash 24.27M 19.13M 13.86M 26.76M 11.79M
Cash and equivalents - - - - -
Total current liabilities 29.88M 25.33M 21.81M 25.14M 20.86M
Current deferred revenue 0.39M - 16.33M 17.52M 14.02M
Net debt -5.17400M -2.53800M 2.08M 28.01M 3.93M
Short term debt 2.47M 1.89M 1.87M 4.45M 1.76M
Short long term debt - - - 2.50M -
Short long term debt total 19.09M 16.60M 15.94M 54.78M 15.71M
Other stockholder equity 186.86M 176.22M 169.23M 103.32M 94.90M
Property plant equipment - 17.90M 32.13M 15.04M 14.85M
Total current assets 188.85M 161.73M 139.88M 94.26M 92.09M
Long term investments - - - - -
Net tangible assets - 155.73M 135.50M 113.67M 108.19M
Short term investments 80.81M 63.56M 56.10M 0.21M 20.89M
Net receivables 25.06M 22.04M 19.63M 19.55M 16.57M
Long term debt - - - 35.53M -
Inventory 52.33M 50.27M 46.10M 45.12M 39.53M
Accounts payable 3.73M 2.90M 2.34M 2.39M 2.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.62500M -6.03100M -3.43500M -1.52500M -4.00700M
Additional paid in capital - - - - -
Common stock total equity - 0.24M 0.23M 0.22M 0.22M
Preferred stock total equity - - - - -
Retained earnings total equity - 97.77M 88.12M 70.55M 57.03M
Treasury stock - -13.04600M -12.40400M -11.60200M -11.03200M
Accumulated amortization - - - - -
Non currrent assets other 9.49M 0.99M 0.57M 0.91M 0.26M
Deferred long term asset charges - - - - -
Non current assets total 157.93M 148.74M 152.92M 158.55M 96.25M
Capital lease obligations 19.09M 16.60M 15.94M 16.75M 15.71M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -22.85600M -8.00000M -56.19400M 20.70M 0.90M
Change to liabilities - 0.65M -1.73400M 4.32M -0.59600M
Total cashflows from investing activities - -10.37100M -61.07600M -52.89100M -24.10000M
Net borrowings - - -39.00000M 37.25M 39.00M
Total cash from financing activities -7.13100M -9.23400M 13.70M 32.16M -4.62200M
Change to operating activities - -3.09600M -1.92700M 0.09M -0.65400M
Net income 30.11M 20.64M 26.91M 21.22M 17.93M
Change in cash 5.13M 5.28M -12.90900M 14.98M -14.53200M
Begin period cash flow 19.13M 13.86M 26.76M 11.79M 26.32M
End period cash flow 24.27M 19.13M 13.86M 26.76M 11.79M
Total cash from operating activities 36.75M 25.38M 35.10M 34.80M 14.18M
Issuance of capital stock 6.86M 3.47M 63.24M 5.97M 4.86M
Depreciation 9.52M 9.43M 11.07M 8.39M 5.42M
Other cashflows from investing activities - 0.86M - -70.60400M -21.24000M
Dividends paid 12.45M 10.99M 9.34M 7.70M 6.74M
Change to inventory -9.79400M -7.41800M -5.48500M -2.60900M -11.33500M
Change to account receivables -3.13500M -3.53300M -0.81800M -0.93900M -1.30100M
Sale purchase of stock -0.85300M -0.64200M -0.80200M -0.57000M -0.68300M
Other cashflows from financing activities 7.13M -1.07000M -0.40100M 60.45M -2.05900M
Change to netincome - 8.71M 7.09M 4.32M 4.71M
Capital expenditures 7.26M 3.23M 4.88M 2.98M 3.76M
Change receivables - -3.53300M -0.81800M -0.93900M -1.30100M
Cash flows other operating - -10.51400M -7.41200M -2.52000M -11.98900M
Exchange rate changes - - - - 0.01M
Cash and cash equivalents changes - 5.77M -12.27200M 14.06M -14.53200M
Change in working capital -11.25400M -13.40200M -9.96400M 0.86M -13.88600M
Stock based compensation 5.32M 4.17M 3.48M 3.02M 2.64M
Other non cash items 2.28M 4.72M 3.53M 1.63M 1.25M
Free cash flow 29.49M 22.15M 30.22M 31.82M 10.42M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LMAT
LeMaitre Vascular Inc
3.09 3.92% 81.91 52.74 38.76 7.46 4.85 7.02 27.72
ISRG
Intuitive Surgical Inc
7.66 1.61% 484.44 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA
0.38 0.27% 143.02 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme
-0.19 0.07% 284.00 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company
3.19 1.43% 225.98 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

Profile

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LeMaitre Vascular Inc

63 Second Avenue, Burlington, MA, United States, 01803

Key Executives

Name Title Year Born
Mr. George W. LeMaitre Chairman & CEO 1965
Mr. David B. Roberts Pres & Director 1964
Mr. Joseph P. Pellegrino Jr. CFO, Treasurer, Sec. & Director 1965
Mr. Trent G. Kamke Sr. VP of Operations 1971
Dr. George D. LeMaitre Founder and Chairman of Scientific Advisory Board 1934
Ms. Laurie A. Churchill Sr. VP & Gen. Counsel 1971
Ms. Kimberly L. Cieslak VP of Marketing 1973
Mr. Daniel J. Mumford Director of HR 1982
Mr. Andrew Hodgkinson Sr. VP of Clinical, Regulatory & Quality Affairs 1976
Mr. Stephane Maier Sr. VP of EMEA Operations 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.